The phase III ESCORT-NEO trial evaluated camrelizumab in combination with chemotherapy versus chemotherapy alone in the ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...

AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

Shares of AstraZeneca PLC AZN inched up 0.05% to £110.46 Thursday, on what proved to be an all-around positive trading ...

AstraZeneca said it has created more than 1,200 jobs and invested more than $1.3-billion CAD in Canada since 2023. The ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.